Inhibrx Biosciences (INBX) Income towards Parent Company (2023 - 2025)
Historic Income towards Parent Company for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$35.3 million.
- Inhibrx Biosciences' Income towards Parent Company rose 1962.43% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 10943.65%. This contributed to the annual value of $1.7 billion for FY2024, which is 80395.57% up from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' Income towards Parent Company is -$35.3 million, which was up 1962.43% from -$28.7 million recorded in Q2 2025.
- Inhibrx Biosciences' 5-year Income towards Parent Company high stood at $1.9 billion for Q2 2024, and its period low was -$92.0 million during Q4 2023.
- In the last 3 years, Inhibrx Biosciences' Income towards Parent Company had a median value of -$45.5 million in 2023 and averaged $139.0 million.
- In the last 5 years, Inhibrx Biosciences' Income towards Parent Company surged by 404884.6% in 2024 and then plummeted by 10154.22% in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' Income towards Parent Company stood at -$92.0 million in 2023, then soared by 47.96% to -$47.9 million in 2024, then grew by 26.34% to -$35.3 million in 2025.
- Its last three reported values are -$35.3 million in Q3 2025, -$28.7 million for Q2 2025, and -$43.3 million during Q1 2025.